



RECEIVED
CENTRAL FAX CENTER
FEB 13 2006

Medtronic®

Facsimile Cover Sheet

MEDTRONIC LAW DEPARTMENT - CONFIDENTIAL

To: United States Patent and
Trademark Office

Telephone:

Facsimile: 571-273-8300

From: Keith M. Campbell, Esq.

Telephone: 763-505-0405

Facsimile: 763-505-0411

Re: Response to Office Action of November 16, 2005
Our Ref. No. P20907.00

Date: February 13, 2006

Pages (including cover page): 18

Attached to this facsimile please find:

- Transmittal Letter
- Response

NOTICE

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS ATTORNEY PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ON THIS TRANSMITTAL FORM. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY KARLA WEIS AT 763-505-0421.

FEB. 13. 2006 11:25AM

MEDTRONIC LAW DEPT

NO. 6639 P. 2/18

RECEIVED
CENTRAL FAX CENTER

FEB 13 2006

PATENT

Docket No.: P-20907.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Hildebrand, et al.	Group Art Unit:	1616
Application No.:	10/808,113	Examiner:	David Paul Stitzel, Esq.
Filing Date:	March 24, 2004	Confirmation No.:	4515
Title:	PROCESS FOR PRODUCING INJECTABLE GABAPENTIN COMPOSITIONS		

I hereby certify that this correspondence is being deposited

via first class mail with the United States Postal Service with sufficient postage to Mail Stop
Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450;

or

facsimile transmitted to the U.S. Patent and Trademark Office
 to 571-273-8300 on Feb. 13, 2006



Karla K. Weis

TRANSMITTAL LETTER**Centralized Facsimile Number 571-273-8300**

Mail Stop: Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

We are transmitting herewith the attached:

- Transmittal Letter
- Response to Office Action
- Petition for Extension of Time
- Return Receipt Postcard
- Other: _____

FEE CALCULATION	No. of Claims Currently Filed	<Less> Highest No. of Claims Previously Paid	No. of Extra Claims	Rate	Fee
Total Claims	38	- 38 =	0	x \$50	\$ 0
Independent Claims	2	- 2 =	0	x \$200	\$ 0
Multiple Dependent Claims		- =		+ \$360	\$

FEB. 13. 2006 11:25AM

MEDTRONIC LAW DEPT


NO. 6639 P. 3/18

*Application No.: 10/808,113
Response to Office Action Mailed: November 16, 2005*

- Please charge Deposit Account No. 13-2546 \$ for additional claims fees and \$ for petition fees, for a total of \$
- Please charge any additional fees or credit any overpayments to Deposit Account No. 13-2546, which may have been overlooked on this Transmittal Letter with regard to this filing.

Respectfully submitted,

Date: 2.13.06



Keith M. Campbell
Registration No. 46,597
MEDTRONIC, INC.
710 Medtronic Parkway NE,
M.S.: LC340
Minneapolis, Minnesota 55432-5604
Telephone: (763) 505-0405
Facsimile: (763) 505-0411
CUSTOMER NO.: 27581

FEB. 13. 2006 11:25AM

MEDTRONIC LAW DEPT

NO. 6639 P. 4/18

RECEIVED
CENTRAL FAX CENTER

FEB 13 2006

PATENT
Docket No.: P-20907.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hildebrand, et al. Group Art Unit: 1616
Application No.: 10/808,113 Examiner: David Paul Stitzel, Esq.
Filing Date: March 24, 2004 Conf. No.: 4515
Title: PROCESS FOR PRODUCING INJECTABLE GABAPENTIN
COMPOSITIONS

CERTIFICATE OF MAILING OR TRANSMISSION:

I hereby certify that this correspondence is being deposited

- via first class mail with the United States Postal Service with sufficient postage to Mail Stop Amendment,
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450; or
 facsimile transmitted to the U.S. Patent and Trademark Office to (571)273-8300 on

Feb. 13, 2006



Karla K. Weis

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RESPONSE

This communication is in response to the Non-Final Office Action mailed November 16, 2005. Please amend the above-identified application as indicated on the attached pages.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 7 of this paper.